A prospective exploratory clinical study of penpulimab plus anlotinib as first-line treatment for locally advanced or metastatic urothelial carcinoma.

被引：0
|
作者：
Yang, Bo
Xiong, Qi
Song, Qi
Long, Yaping
Guo, Gang
Li, Hongzhao
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, First Med Ctr, Dept Oncol, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Med Oncol, Beijing, Peoples R China
[4] Med Ethics Comm Chinese PLA Gen Hosp, Beijing, Peoples R China
[5] Chinese Peoples Liberat Army Gen Hosp, First Med Ctr, Dept Urol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4567
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder
    E. El Rassy
    T. Assi
    Z. Bakouny
    N. Pavlidis
    J. Kattan
    Clinical and Translational Oncology, 2019, 21 : 280 - 288
  • [32] Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma
    Miron, Benjamin
    Geynisman, Daniel M.
    EUROPEAN UROLOGY, 2022, 82 (04) : 374 - 376
  • [33] Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder
    El Rassy, E.
    Assi, T.
    Bakouny, Z.
    Pavlidis, N.
    Kattan, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (03): : 280 - 288
  • [34] Phase II trial of gemcitabine and cisplatin plus ipilimumab as first-line treatment for metastatic urothelial carcinoma
    Gartrell, Benjamin Adam
    Hahn, Noah M.
    Hutson, Thomas E.
    Sonpavde, Guru
    Hauke, Ralph J.
    Starodub, Alexander
    Small, Alexander C.
    Tsao, Che-Kai
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] ALTN-AK105-II-02 cohort 4: A phase II study of penpulimab plus anlotinib in patients (pts) with previously treated locally advanced or metastatic urothelial carcinoma (UC)
    Sun, Y.
    Qu, W.
    Sun, M.
    Zhou, J.
    Bi, X.
    Zhou, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1334 - S1334
  • [36] CaboCombo: A prospective international non-interventional study of first-line cabozantinib plus nivolumab for the treatment of patients with advanced renal cell carcinoma.
    Barthelemy, Philippe
    Dutailly, Pascale
    Qvick, Bryan
    Perrot, Valerie
    Verzoni, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [37] First-line maintenance therapy in patients with locally advanced or metastatic urothelial carcinoma in routine care in Germany: Preliminary results of the prospective CARAT registry
    Goebell, P. J.
    Radkowski, R.
    Mueller, L.
    Ghasemi, U.
    Gruenwald, V.
    Deger, S.
    Andres-Pons, A.
    Lennartz, C.
    Jaenicke, M.
    Gruellich, C.
    Staehler, M.
    Gratzke, C.
    Potthoff, K.
    EUROPEAN UROLOGY, 2024, 85 : S1731 - S1731
  • [38] Real-world first-line treatment patterns and outcomes in patients with locally advanced or metastatic urothelial carcinoma in the United States.
    Chen, Ronald C.
    Mucha, Lisa
    Nimke, David
    Young, Christopher
    Yang, Hongbo
    Liu, Qing
    Greatsinger, Alexandra
    Zhang, Adina
    Wright, Phoebe
    Quicquaro, Christina Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] SIMULATING THE IMPACT OF FIRST-LINE TREATMENT CHOICE ON SURVIVAL AMONG PATIENTS WITH LOCALLY ADVANCED/METASTATIC UROTHELIAL CARCINOMA CONSIDERED CISPLATIN INELIGIBLE
    Galsky, M. D.
    Sonpavde, G. P.
    Bloudek, B.
    Farrar, M.
    Hepp, Z.
    Timmons, J.
    Dillon, R.
    Powles, T.
    VALUE IN HEALTH, 2023, 26 (06) : S18 - S18
  • [40] A meta-analysis assessing objective response rates with first-line systemic treatment options in locally advanced/metastatic urothelial carcinoma
    Saxena, Akshat
    Naqvi, Syed Arsalan Ahmed
    Tripathi, Nikita
    Khan, Muhammad Ali
    Bibi, Arifa
    Ballouz, Tara
    Abdul-Muhsin, Haidar
    Tyson, Mark
    Bin Riaz, Irbaz
    Bryce, Alan Haruo
    Singh, Parminder
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 639 - 639
12345